Vaccinex, Inc. (VCNX) income statement
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2024, quý kết thúc ngày Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex, Inc. income statement
Ratios
Latest available, balances at Dec 31, 2024
Profitability, TTM
- Gross margin
- –
- Operating margin
- -3117.3%
- Net margin
- -3100.5%
- Return on equity, FY2024
- –
Financial strength
- Current ratio
- 0.50
- Debt to equity
- –
- Debt to assets
- 1.0%
- Cash to current liabilities
- 21.8%
Valuation
- P/E ratio
- –
- Price to sales
- 5.36
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?